Unser Referententeam vor Ort

15 Experten präsentieren die aktuellen Studienergebnisse

  • Prof. Peter Borchmann
    Prof. Peter Borchmann Uniklinik Köln
    Prof. Peter Borchmann

    Non-Hodgkin-Lymphome: DLBCL und CAR-T Zellen

    Consultancy: Celgene, MSD; Novartis, Takeda
    Research Funding: MSD, Novartis, Takeda
    Honoraria: Amgen, Bristol-Myers Squibb, MSD, Novartis, Roche, Takeda
    Patents and Royalties: not applicable
    Membership on an entity’s Board of Directors or advisory committees: not applicable
    Discussion of off-label drug use: not applicable

  • Prof. Tim Henrik Brümmendorf
    Prof. Tim Henrik Brümmendorf Uniklinik RWTH Aachen
    Prof. Tim Henrik Brümmendorf

    Chronische Myeloische Leukämie:
    Neue Therapieansätze

    Consultancy: Novartis, Pfizer
    Research Funding: Novartis, Pfizer
    Honoraria: not applicable
    Patents and Royalties: Combination of Imatinib with Hypusination Inhibitors (Novartis)
    Membership on an entity’s Board of Directors or advisory committees: not applicable
    Discussion of off-label drug use: if off label drug use is discussed, it will be indicated appropriately

  • Prof. Lars Bullinger
    Prof. Lars Bullinger Charité – Universitätsklinik Berlin
    Prof. Lars Bullinger

    Akute Myeloische Leukämie

    Consultancy: not applicable
    Research Funding: Bayer
    Honoraria: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Jazz, Pharmaceuticals, Novartis, Pfizer, Sanofi, Seattle Genetics
    Patents and Royalties: not applicable
    Membership on an entity’s Board of Directors or advisory committees: Bristol-Myers Squibb, Janssen, Novartis, Pfizer
    Discussion of off-label drug use: not applicable

  • Prof. Holger Cario
    Prof. Holger Cario Universitätsklinikum Ulm
    Prof. Holger Cario

    Hämoglobinopathien und Eisenüberladung

    Consultancy: not applicable
    Research Funding: not applicable
    Honoraria: ApoPharma, Celgene, Novartis
    Patents and Royalties: not applicable
    Membership on an entity’s Board of Directors or advisory committees: Celgene, Novartis
    Discussion of off-label drug use: not applicable

  • Prof. Martin Dreyling
    Prof. Martin Dreyling Klinikum der Universität München
    Prof. Martin Dreyling

    Non-Hodgkin-Lymphome: FL, MCL, MZL und Waldenström

    Scientific Advisory Board: Acerta, Bayer, Celgene, Gilead, Janssen, Novartis, Roche, Sandoz
    Research Funding (Institution): Celgene, Janssen, Mundipharma, Roche
    Honoraria: Bayer, Celgene, Gilead, Janssen, Roche
    Patents and Royalties: not applicable
    Membership on an entity’s Board of Directors or advisory committees: not applicable
    Discussion of off-label drug use: not applicable

  • PD Dr. Barbara Eichhorst
    PD Dr. Barbara Eichhorst Uniklinik Köln
    PD Dr. Barbara Eichhorst

    Chronisch Lymphatische Leukämie

    Consultancy: Abbvie, Celgene, Gilead, Janssen, Novartis, Roche
    Research Funding: Abbvie, Gilead, Janssen, Roche
    Honoraria: Abbvie, Celgene, Gilead, Janssen, Pharmacyclics
    Patents and Royalties: not applicable
    Membership on an entity’s Board of Directors or advisory committees: not applicable
    Discussion of off-label drug use: not applicable

  • Prof. Andreas Engert
    Prof. Andreas Engert Uniklinik Köln
    Prof. Andreas Engert

    Hodgkin-Lymphom

    Consultancy: Bristol-Myers Squibb, Takeda/Millennium
    Research Funding: Affimed, Bristol-Myers Squibb, Takeda/Millennium
    Honoraria: Bristol-Myers Squibb, Chugai, Hexal, MSD, Takeda/Millennium
    Patents and Royalties: not applicable
    Membership on an entity’s Board of Directors or advisory committees: Novartis
    Discussion of off-label drug use: yes

  • Dr. Nicola Gökbuget
    Dr. Nicola Gökbuget Universitätsklinikum Frankfurt am Main
    Dr. Nicola Gökbuget

    Akute Lymphatische Leukämie

    Consultancy: AMGEN, Celgene, Erytech, Jazz Pharmaceuticals, Kite/Gilead, Pfizer, Shire/Baxalta/Servier
    Research Funding: AMGEN, Jazz Pharmaceuticals, Novartis, Pfizer, Shire/Baxalta/Servier
    Honoraria/Invited Speaker: AMGEN, Jazz Pharmaceuticals, Novartis, Pfizer, Shire/Baxalta/Servier
    Patents and Royalties: not applicable
    Membership on an entity’s Board of Directors or advisory committees: not applicable
    Discussion of off-label drug use: not applicable

  • Prof. Hartmut Goldschmidt
    Prof. Hartmut Goldschmidt Universitätsklinikum Heidelberg
    Prof. Hartmut Goldschmidt

    Multiples Myelom

    Consultancy: AMGEN, Bristol-Myers Squibb, Celgene, Novartis, Janssen
    Research Funding: Bristol-Myers Squibb, Celgene, Chugai, Janssen, Novartis
    Honoraria: Bristol-Myers Squibb, Celgene, Chugai, Janssen, Novartis
    Patents and Royalties: not applicable
    Membership on an entity’s Board of Directors or advisory committees: not applicable
    Discussion of off-label drug use: not applicable

  • Prof. Martin Griesshammer
    Prof. Martin Griesshammer Johannes Wesling Universitätsklinikum, Minden
    Prof. Martin Griesshammer

    Therapie der klassischen Myeloproliferativen Neoplasien

    Consultancy: not applicable
    Research Funding: not applicable
    Honoraria: Amgen, AOP orphan, Celgene, CTI, Janssen, Novartis, Roche, Shire
    Patents and Royalties: not applicable
    Membership on an entity’s Board of Directors or advisory committees: not applicable
    Discussion of off-label drug use: not applicable

  • Prof. Wolf-Karsten Hofmann
    Prof. Wolf-Karsten Hofmann Universitätsmedizin Mannheim
    Prof. Wolf-Karsten Hofmann

    Myelodysplastisches Syndrom

    Consultancy: Apogenix
    Research Funding: Apogenix, Celgene, Novartis
    Honoraria: Celgene, Novartis
    Patents and Royalties: not applicable
    Membership on an entity’s Board of Directors or advisory committees: not applicable
    Discussion of off-label drug use: not applicable

  • Prof. Nicolaus Kröger
    Prof. Nicolaus Kröger Universitätsklinikum Hamburg-Eppendorf
    Prof. Nicolaus Kröger

    Stammzelltransplantation

    Consultancy: Jazz Pharmaceuticals, Medac
    Research Funding: Celgene, Neovii, Novartis, Riemser, Sanofi
    Honoraria: Jazz Pharmaceuticals, Neovii, Novartis, Riemser, Sanofi
    Patents and Royalties: not applicable
    Membership on an entity’s Board of Directors or advisory committees: not applicable
    Discussion of off-label drug use: not applicable

  • Prof. Axel Matzdorff
    Prof. Axel Matzdorff Asklepios Klinikum Uckermark
    Prof. Axel Matzdorff

    Immunthrombozytopenie

    Consultancy: AMGEN, Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Leo Pharma
    Research Funding: Leo Pharma
    Honoraria: AMGEN, Aspen, Astra, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline„ Leo Pharma, Novartis, Pfizer, Roche, Sanofi
    Patents and Royalties: not applicable
    Membership on an entity’s Board of Directors or advisory committees: AMGEN, Bristol-Myers Squibb, GlaxoSmithKline, Leo Pharma, Novartis
    Discussion of off-label drug use: yes

  • Prof. Andreas Reiter
    Prof. Andreas Reiter Universitätsmedizin Mannheim
    Prof. Andreas Reiter

    MPN Diagnostik, seltene MPN und AdvSM

    Consultancy: Blueprint, CTI, Deciphera, Incyte, Novartis
    Research Funding: Novartis
    Honoraria: Blueprint, CTI, Deciphera, Incyte, Novartis
    Patents and Royalties: not applicable
    Membership on an entity’s Board of Directors or advisory committees: not applicable
    Discussion of off-label drug use: not applicable

  • Prof. Susanne Saußele
    Prof. Susanne Saußele Universitätsmedizin Mannheim
    Prof. Susanne Saußele

    Chronische Myeloische Leukämie: Therapiefreie Remission

    Consultancy: not applicable
    Research Funding: Bristol-Myers Squibb, Novartis
    Honoraria: Bristol-Myers Squibb, Incyte, Novartis, Pfizer
    Patents and Royalties: not applicable
    Membership on an entity’s Board of Directors or advisory committees: not applicable
    Discussion of off-label drug use: not applicable